Trials / Conditions / Complement 3 Glomerulopathy
Complement 3 Glomerulopathy
5 registered clinical trials studyying Complement 3 Glomerulopathy.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531 | Apellis Pharmaceuticals, Inc. | Phase 3 |
| Terminated | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy NCT05162066 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127 | Apellis Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN NCT04572854 | Apellis Pharmaceuticals, Inc. | Phase 2 |
| Approved For Marketing | C3G/Primary IC-MPGN EAP NCT04729062 | Apellis Pharmaceuticals, Inc. | — |